Centene CorporationNYSE: CNC
Health Care · Managed Health Care
$60.99
+0.58%
Vol: 3.7M
Research Digest
Friday, June 19, 2026
Centene offers voluntary buyouts to most of its 61,000 employees as ACA membership drops nearly 40%, with layoffs likely if headcount targets are not met voluntarily.
Centene Corp offered voluntary buyouts to the majority of its workforce on June 15, 2026, after ACA membership fell roughly 2 million members in Q1 2026 following the expiration of enhanced federal subsidies. The company expects ACA enrollment to decline nearly 40% by year-end 2026, making structural cost reduction necessary. Centene raised its full-year 2026 adjusted diluted EPS guidance above $3.40 despite the membership headwinds. The stock has surged approximately 58% in 2026 year-to-date, and Bernstein maintained a Buy rating on June 9. Layoff risk remains if voluntary exit targets are not reached, which could pressure morale and operational continuity.
Previous Market Intelligence
13 daysJun 18Centene to offer voluntary buyouts to most of its ~61,000 employees amid steep ACA membership losses, with layoffs possible if uptake falls short.Negative▶
On June 15, 2026, Bloomberg reported that Centene will offer voluntary separation buyouts to the bulk of its roughly 61,000 employees as it restructures following a sharp drop in health-plan membership, and CNC shares fell nearly 4% on the news. The buyouts are not guaranteed or automatic, and layoffs could follow if the number of employees accepting the offer falls short of internal cost-reduction goals. The pressure stems from Centene losing about 2 million Affordable Care Act members this year, contributing to a 6% decline in total health-plan membership to 26.27 million as of March 31. While Q1 2026 results beat (EPS $3.37 vs. $2.08 estimate) and the company raised full-year guidance and cut $1 billion in debt, the membership erosion threatens future profitability. The buyout move signals management is bracing for a smaller revenue base. The risk is that cost cuts and shrinking membership pressure the long-term earnings trajectory even as near-term results hold up.
Jun 17Centene to offer buyouts to most of its ~61,000 employees amid steep membership losses, signaling deepening cost pressure in its government health plans.Negative▶
On June 15, 2026, Bloomberg reported that Centene will offer voluntary buyouts to most of its roughly 61,000 employees, with job layoffs potentially to follow, as the insurer cuts costs in response to rising medical costs, funding cuts and sharp membership declines. The company has lost about 2 million Affordable Care Act members this year after pandemic-era subsidies expired, and total membership fell 6% year-over-year in Q1 2026 to about 26.3 million. Centene is forecasting 2026 revenue of roughly $189.5 billion at the midpoint, down about 3% from 2025. CNC shares fell nearly 4% on Monday following the report. The move underscores margin and enrollment risk in Centene's core Medicaid and ACA businesses, though the stock is still up sharply in 2026. The key risk is that buyouts signal a structural membership and profitability problem rather than a one-time adjustment.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Centene refreshed executive leadership and raised 2026 EPS outlook to above $3.40 amid Q1 beatPositive▶
Centene on May 12, 2026 confirmed an executive officer slate including Daniel Finke as Group President of Medicaid and Marketplace and Michael Carson as Group President of Medicare and Specialty under CEO Sarah London. The company raised its 2026 adjusted EPS guidance to greater than $3.40 after Q1 EPS of $3.37 substantially beat consensus near $2.13-$2.23. Shares surged 6% to $59.31 on May 12 amid healthcare sector recovery. Recent analyst actions include TD Cowen raising the price target to $48 and BofA upgrading to Buy. The stock outperformed 77% of all stocks and trades near its 52-week high. Risk: medical cost pressures and ongoing margin concerns in government-sponsored health programs remain key.
May 20Centene confirmed leadership team May 12, raises FY26 EPS guidance above $3.40 after Q1 beat.Positive▶
Centene's board on May 12, 2026 confirmed Sarah London as CEO, Drew Asher as CFO, Daniel Finke as Group President of Medicaid and Marketplace, and Michael Carson as Group President of Medicare and Specialty, formalizing leadership amid higher medical costs and federal policy shifts. Q1 2026 results (reported April 28) showed GAAP diluted EPS of $3.11 and adjusted diluted EPS of $3.37, beating prior management views by $0.50. The company raised 2026 GAAP EPS guidance to greater than $2.37 and adjusted EPS to greater than $3.40. TD Cowen raised its price target to $48 from $38 on May 4 (Hold). Superior HealthPlan launched a Texas behavioral health quality recognition program in early May. Analyst average rating across 16 analysts is "Buy."
May 19Centene names full executive officer slate on May 12 8-K, including Sarah London as CEO and Drew Asher as CFO; shares surge 6% to $59.31Positive▶
On May 12, 2026, Centene's board affirmed its executive officer roster, including Sarah London as CEO, Drew Asher as CFO, Daniel Finke leading Medicaid and Marketplace, Michael Carson leading Medicare and Specialty, Susan Smith as COO, and Christopher Koster as General Counsel. Shares jumped 6.0% to $59.31 the same day amid a healthcare-sector recovery. Q1 2026 reported revenue of about $46.3 billion and adjusted diluted EPS of $2.90, with management subsequently raising FY2026 adjusted EPS guidance to greater than $3.40. On May 5, Superior HealthPlan designated three Texas providers as Mental Health Rehabilitation and Targeted Case Management Centers of Excellence. TD Cowen raised its CNC price target to $48 from $38 on May 4 while maintaining Hold. Risk: medical-cost trend remains the dominant variable for the managed-care thesis even as guidance moves up.
May 18Centene shares surged 6% to $59.31 on May 12 as board confirmed refreshed leadership and TD Cowen raised PT to $48 from $38Positive▶
Centene Corp shares surged 6.0% to $59.31 on May 12 amid healthcare sector recovery. The board confirmed a refreshed senior leadership roster including CEO Sarah London, CFO Drew Asher, COO Susan Smith, plus new Group Presidents Daniel Finke (Medicaid/Marketplace) and Michael Carson (Medicare/Specialty). Shareholders at the annual meeting re-elected nine directors, approved executive compensation, ratified KPMG as auditor, and rejected an independent board chair proposal. TD Cowen raised PT to $48 from $38 (reaffirming Hold). The stock has surged over 56% in a month, with a 52-week range of $25.08-$62.21. Earlier Q1 results showed adjusted EPS of $3.37 and raised 2026 GAAP EPS guidance to >$3.40.
May 15Centene shares surge 6% to $59.31 on May 12 amid sector recovery; TD Cowen lifts price target to $48Positive▶
Centene shares jumped 6.0% to $59.31 on May 12, 2026, extending a 29.1% rally since April 24 as health insurer results have outperformed. TD Cowen raised its CNC price target to $48 from $38 (Hold) on May 4. On May 5, Centene's Superior HealthPlan subsidiary designated three Texas providers as Mental Health Rehabilitation and Targeted Case Management Centers of Excellence. Q1 2026 adjusted EPS of $3.37 came in $0.50 better than management's prior view, prompting raised 2026 premium revenue guidance of $171B-$175B and adjusted EPS guidance above $3.40. The company also cited stronger-than-expected ACA marketplace retention. According to 16 analysts the average rating is Buy with a $47.5 12-month target. Sentiment has flipped positive after a difficult start to the year.
May 14Centene shares jump 6% to $59.31 on May 12 as Q1 EPS of $3.37 crushes estimate and 2026 guidance raisedPositive▶
Centene shares surged 6% to $59.31 on May 12, extending a 29% rally since April 24. Q1 2026 results delivered total revenue of $49.9B, GAAP EPS of $3.11 (vs. $2.63 prior year), and adjusted EPS of $3.37 vs. $2.08 estimate. The company raised 2026 guidance with premium and service revenue at $171.0-$175.0B and adjusted EPS floor lifted above $3.40, driven by better-than-expected ACA marketplace retention. TD Cowen raised its PT to $48 from $38, maintaining Hold. Cantor Fitzgerald upgraded to Overweight from Neutral. Stock up 34.5% YTD, outperforming the medical sector.
May 13Centene shares jumped ~29% since April 24 after Q1 2026 adj EPS of $3.37 crushed $2.08 consensus and 2026 guidance was raised.Positive▶
Centene posted Q1 2026 GAAP EPS of $3.11 and adjusted EPS of $3.37, well above $2.08 consensus, on $49.9B revenue. The company raised 2026 guidance, lifting premium/service revenue range to $171-175B and adjusted EPS floor above $3.40 from prior >$3.00. Better-than-expected ACA marketplace retention was a focal point of the call. The stock surged ~29% since insurers' earnings season kicked off April 24, trading near $59.31 on May 13. TD Cowen raised its target to $48 on May 4 while Wells Fargo and Mizuho maintained Hold. Superior HealthPlan designated three Texas Mental Health Centers of Excellence on May 5. Risk is Medicaid redetermination and ACA subsidy expiration headlines.
May 12Centene shares jumped after Q1 2026 EPS of $3.37 beat estimates by 62% and the insurer raised 2026 guidance, with the stock up about 29% since April 24.Positive▶
Centene reported Q1 2026 adjusted EPS of $3.37 versus $2.08 consensus, with total revenue of $49.9 billion and premium and service revenue of $44.7 billion, up 5% year-over-year. Management lifted 2026 guidance, increasing premium and service revenue expectations to $171.0-$175.0 billion and floors for GAAP EPS above $2.37 and adjusted EPS above $3.40. Better-than-expected ACA marketplace membership retention was a key driver, alongside cost controls. Cantor Fitzgerald upgraded the shares to Overweight with a $60 target while TD Cowen raised its target to $48. Year-to-date the stock is up roughly 34.5%, sharply outperforming the medical sector. Risk: average analyst 12-month target sits near $47.5.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| UNHUNITEDHEALTH | $400.38 | +0.21% | -0.3% | 20.3x | 0.63 | $386.3B |
| ELVELEVANCE | $388.43 | -0.73% | +0.4% | 14.3x | 0.68 | $90.7B |
| HUMHUMANA | $360.23 | -0.49% | -3.1% | 25.2x | 0.72 | $47.6B |
| CNCCENTENE | $60.99 | +0.58% | -0.7% | 15.2x | 1.08 | $33.5B |
| MOHMOLINA | $195.55 | +0.01% | -1.1% | 24.6x | 0.74 | $12.0B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.